Clinically substantial immune-mediated hematologic adverse reactions (including hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) transpired at an incidence of less than 1% in patients who been given this drug or ended up reported with using other PD-1/PD-L1 blocking antibodies.According to how serious your reaction is, your docto… Read More